4147.TWO

TaiMed Biologics Inc. [4147.TWO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

4147.TWO Stock Summary

In the News

4147.TWO Financial details

Company Rating
-
Market Cap
23.78B
Income
-198.34M
Revenue
491.78M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
79
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-142.8
Forward P/E
-
PEG
49.09
P/S
33.35
P/B
9.67
P/C
-
P/FCF
-358.82
Quick Ratio
2.26
Current Ratio
6.05
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.77
EPS next Y
-
EPS next Q
-
EPS this Y
-30.28%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-19.58%
Revenue last 5Y
-6.94%
Revenue Q/Q
0.42%
EPS Q/Q
904.37%
-
-
-
-
SMA20
-11.86%
SMA50
-21.21%
SMA100
-31.58%
Inst Own
-
Inst Trans
-
ROA
-4%
ROE
-7%
ROC
-0.04%
Gross Margin
43%
Oper. Margin
-24%
Profit Margin
-27%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
76.3-135.0
52W High
-60.37%
52W Low
-29.61%
RSI
45
Rel Volume
0.45
Avg Volume
2.34M
Volume
1.04M
Perf Week
3.28%
Perf Month
-12.3%
Perf Quarter
-33.62%
Perf Half Y
-33.62%
-
-
-
-
Beta
0.458
-
-
Volatility
1.22%, 3.46%
Prev Close
-1.47%
Price
53.5
Change
0.75%

Something similar

Top by Market Cap
AMZ.DE
BRH.DE
MIX.JO
FB2A.DE
LLY.SW
Same Sector
0HG8.L
GNRSW
ROQ.L
NBRV
PROMO.ST
Same Price Range
2342.TW
QGRW
WMAT.L
CIBR
UT8.DE
Similar Market Cap
3661.T
THISX
0HKE.L
002595.SZ
TNE5.DE

Company Profile

Healthcare Biotechnology
  • Volume Average 2.34M
  • Market Capitalization 23.78B
  • Employee 79
  • CEO Mr. Chin-Ming Chang Ph.D.
  • Headquarters Taipei,TW
  • IPO Date 2012-06-20
  • Website https://www.taimedbiologics.com

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases. The company develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.